From Financial Modeling Prep: 2025-02-25 07:00:03

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) struggles with a negative ROIC of -137.82% compared to a WACC of 8.12%, indicating inefficiency in generating returns above its cost of capital. In contrast, Biotricity, Inc. (BTCY) excels with a ROIC of 138.03% and a WACC of 19.17%, showcasing effective capital utilization. Other companies like InMed Pharmaceuticals Inc. (INM), NeuroBo Pharmaceuticals, Inc. (NRBO), and Palisade Bio, Inc. (PALI) also face challenges with negative ROICs and struggle to achieve positive capital returns.



Read more at Financial Modeling Prep:: Comparative Analysis of ROIC and WACC in the Medic…